Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

. 2017 Aug 10;8(40):68938-68949.
doi: 10.18632/oncotarget.20196. eCollection 2017 Sep 15.

Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients (V体育平台登录)

Quan Zhou  1   2 , Li Hong  2 , Man-Zhen Zuo  1 , Ze He  1
Affiliations

Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients

Quan Zhou et al. Oncotarget. .

VSports最新版本 - Abstract

Increasing evidence indicates that elevated neutrophil to lymphocyte ratio (NLR) are related with poor prognosis in various types of tumors. However, the prognostic role of NLR in patients with ovarian cancer (OC) remains controversial. Thus, the current meta-analysis aimed to investigate the prognostic role of NLR in patients with OC. A total of 16 studies with 4,910 patients were included. By pooling hazard ratios (HRs) with 95% confidence intervals (CIs) and odds ratios (ORs) with 95% CIs from each study. The results demonstrated that elevated pretreatment NLR was significantly related to poor OS (HR: 1. 50, 95% CI: 1. 27-1. 77) and PFS (HR: 1. 53, 95% CI: 1 VSports手机版. 28-1. 84) in patients with OC. Subgroup analyses was divided by ethnicity, sample size, histologic types, cut-off value of NLR, analysis method and NOS score, but the results did not showed any significant change the main results. This meta-analysis revealed that elevated pretreatment NLR might be a predicative factor of poor prognosis in OC patients. .

Keywords: neutrophil to lymphocyte ratio; ovarian cancer; prognostic value. V体育安卓版.

PubMed Disclaimer

"VSports手机版" Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

VSports app下载 - Figures

Figure 1
Figure 1. Flow chart showing the process for selecting eligible studies in the meta-analysis
Figure 2
Figure 2. The forest plot between elevated NLR and OS in patients with OC
Figure 3
Figure 3. The forest plot between elevated NLR and PFS in patients with OC
Figure 4
Figure 4
Sensitivity analysis of NLR on OS (A) and PFS (B) in OC patients.
Figure 5
Figure 5
Funnel plot adjusted using the trim and fill method for OS (A) and PFS (B) in patients with OC. Circles: included studies. Diamonds: presumed missing studies.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. https://doi.org/10.3322/caac.21387 (V体育平台登录) - DOI - PubMed
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. V体育安卓版 - https://doi.org/10.3322/caac.21262 - DOI - PubMed
    1. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW, Wender RC. Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2017 https://doi.org/10.3322/caac.21392 - DOI - PubMed
    1. Kim SJ, Rosen B, Fan I, Ivanova A, McLaughlin JR, Risch H, Narod SA, Kotsopoulos J. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. Br J Cancer. 2017;116:964–971. https://doi.org/10.1038/bjc.2017.35 - DOI - PMC - PubMed
    1. Soletormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC, Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the european group on tumor markers. Int J Gynecol Cancer. 2016;26:43–51. https://doi.org/10.1097/IGC.0000000000000586 - DOI - PMC - PubMed